AI-ACCELERATED DRUG DISCOVERY

Focused On-demand Library for DNA-directed primase/polymerase protein

Available from Reaxense
Predicted by Alphafold

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

The specialised, focused library is developed on demand with the most recent virtual screening and parameter assessment technology, guided by the Receptor.AI drug discovery platform. This approach exceeds the capabilities of traditional methods and offers compounds with higher activity, selectivity, and safety.

From a virtual chemical space containing more than 60 billion molecules, we precisely choose certain compounds. Our collaborator, Reaxense, aids in their synthesis and provision.

The library includes a list of the most effective modulators, each annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Furthermore, each compound is shown with its optimal docking poses, affinity scores, and activity scores, offering a detailed summary.

We employ our advanced, specialised process to create targeted libraries for enzymes.

 Fig. 1. The sreening workflow of Receptor.AI

The procedure entails thorough molecular simulations of the catalytic and allosteric binding pockets, accompanied by ensemble virtual screening that factors in their conformational flexibility. When developing modulators, the structural modifications brought about by reaction intermediates are factored in to optimize activity and selectivity.

Our library distinguishes itself through several key aspects:

  • The Receptor.AI platform integrates all available data about the target protein, including past experiments, literature data, known ligands, structural information and more. This consolidated approach maximises the probability of prioritising highly relevant compounds.
  • The platform uses sophisticated molecular simulations to identify possible binding sites so that the compounds in the focused library are suitable for discovering allosteric inhibitors and the binders for cryptic pockets.
  • The platform integrates over 50 highly customisable AI models, which are thoroughly tested and validated on a multitude of commercial drug discovery programs and research projects. It is designed to be efficient, reliable and accurate. All this power is utilised when producing the focused libraries.
  • In addition to producing the focused libraries, Receptor.AI provides services and end-to-end solutions at every stage of preclinical drug discovery. The pricing model is success-based, which reduces your risks and leverages the mutual benefits of the project's success.

partner

Reaxense

upacc

Q96LW4

UPID:

PRIPO_HUMAN

Alternative names:

Coiled-coil domain-containing protein 111

Alternative UPACC:

Q96LW4; A0A0A0MTC0; D3DP55; D6RDM1; Q5HYJ9

Background:

The DNA-directed primase/polymerase protein, also known as Coiled-coil domain-containing protein 111, plays a crucial role in DNA replication and repair. It facilitates the bypass of replication-stalling lesions and is essential for both mitochondrial and nuclear DNA synthesis. This protein's ability to tolerate DNA damage lesions and reinitiate stalled replication forks underscores its importance in maintaining genomic stability.

Therapeutic significance:

Linked to Myopia 22, autosomal dominant, this protein's mutation highlights its clinical relevance. Understanding the role of DNA-directed primase/polymerase protein could open doors to potential therapeutic strategies, especially in enhancing DNA repair mechanisms in genetic disorders and improving outcomes in cancer therapy.

Looking for more information on this library or underlying technology? Fill out the form below and we'll be in touch with all the details you need.
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.
No Spam. Cancel Anytime.